Recce Pharmaceuticals Ltd. Stock

Highlights:

-          US Department of Defense grants funding of US$2 million (approximately A$3 million)

-          Funding to accelerate development of RECCE® 327 Gel (R327G) for

Highlights:

-          RECCE® 327 (R327) demonstrates significant bactericidal activity against ‘superbug’ Acinetobacter baumannii (A. baumannii) in adult human epidermal ‘skin’ cells:

Highlights:

-          Phase I/II rapid infusion clinical trial demonstrates efficacy on bacterial growth in dosed participants injected with RECCE® 327 (R327) at the highest tested dose of

Highlights:

-          Global recognition by the World Health Organization (WHO) – inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance

-         

Highlights:

-          RECCE® 327 (R327) demonstrates efficacy in treating Mycobacterium abscessus lung infections using recently developed nebuliser delivery method: >99% log reduction

-          Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024.

-          Recce chosen as one of 18

Highlights:

-          Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II UTI/Urosepsis Trial with an increase in dosage expected to begin in the next several weeks

-

Highlights:

-          Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana Biotechnologies

-          MoU aims to facilitate late-stage clinical trials

Highlights:

-          Positions RECCE® 327 (R327) Gel as potential broad application topical therapeutic for all bacterial skin infections, formally referred to as complicated skin and

SYDNEY Australia, 18 June 2024: Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce a

Highlights:

-          Dosing of 6 human subjects complete in Phase I/II UTI/Urosepsis fast infusion intravenous study of RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to

Highlights:

-          First participants (male/female) successfully dosed at 4,000mg (I.V.), over 20 minutes, 4,000mg highest dosage to date in this clinical trial

-          RECCE® 327

Sydney Australia, 7 May 2024: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the China National

Highlights:

-          Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaign.

-          R327 manufactured under GMP

Highlights:

-          Dosing of 4 clinical subjects complete in Phase I/II UTI/Urosepsis fast infusion I.V. study of RECCE® 327 at 3,000mg over 20 minutes

-          Data received from

Highlights:

-          Independent Safety Committee analysis complete; unanimously clears next clinical intravenous (I.V.) dosing go-ahead

-          Next cohort of human participants will

Sydney Australia, 8 March 2024: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (the Company), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce AUD

Independent Safety Committee Approves Expansion of Phase I/II Clinical Trial for Diabetic Foot Infection Treatment

Highlights:

-          Independent Safety Committee unanimously agrees